For Your Information
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.
The Federal Trade Commission has closed its investigation into Roche Holding AG’s proposed acquisition of Spark Therapeutics, Inc.
According to a Commission Statement, after an exhaustive, 10-month investigation into whether the merger would lessen potential competition in the U.S. market for hemophilia A therapies, the evidence “did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its hemophilia A gene therapy, or that the acquisition would affect Roche’s incentives regarding [its hemophilia treatment drug] Hemlibra.”
The Commission vote to close the investigation was 5-0.
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Contact Information
MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707